Lyka Labs Announces Out-Licensing Deal With US-Based Generics Company


Lyka Labs, a pharmaceutical company on Tuesday announced that it has entered an out-licensing/ technology transfer deal for a basket of 12 Sterlite Injectable Formulations for manufacturing, sales and distribution in the United States of America.

The market size of the licensed formulations is close to $1.4 billion as per IMS MAT March 2017. Lyka Labs will be eligible for a royalty on end sales.

The stock of the company has is up by 3.3% on the NSE at 1020 hours. The stock has delivered negative returns of 30% in a period of one year and has underperformed the BSE Small cap and BSE Healthcare indices over the same time span.

Lyka Labs Limited is engaged in the business of pharmaceutical products and pharma-related activities, including research. The company's principal business activity is formulation.

For Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔
Share on Google Plus

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.

0 comments: